Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGLE-102 in deep second degree burns
NCT05078385Phase 1Completed
- Sponsor
- Aegle Therapeutics
- Start
- Aug 2023
- Primary completion
- Sep 2024
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AGLE-102 in Thermal Burn, sponsored by Aegle Therapeutics. Primary endpoint: Incidence of Adverse Events at 1 year. Started Aug 2023; status: completed.
02
Drugs
AGLE-102
03
Conditions
Thermal Burn
Beyond the preview
Go deeper on NCT05078385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05078385.